The BioMaryland Center and the Medicen Paris Region have agreed to co-fund a new biotechnology project.
Two potentially life-saving technologies, developed 4,000 miles apart, will soon join together thanks to a partnership of the BioMaryland Center and the Medicen Paris Region. The Maryland Department of Business and Economic Development (DBED) announced the international project on Wednesday, from the BIO International Conference 2014 in San Diego.
The new collaborative effort is expected to result in the further development and commercialization of a bacterial detection device.
Opticul Diagnostics, based in Rockville, Maryland, is developing bacterial detection without the use of reagents to produce chemical reactions. Diafir, based in Rennes, France, produces a complementary product that eliminates the need for culture of the organism prior to detection. Its diagnostic solutions are based on infrared sensors to produce a more rapid, minimally invasive approach to detect infections, track metabolic diseases and identify tumors.
“We are excited as this funding will help Opticul move to the point of care space and facilitate our connection with Diafir,” Gallya Gannot, president and founder of Opticul, said in a statement.
“This funding is a great opportunity for Diafir to expand technologically and to penetrate to the medical point of care with a powerful bacterial identification device. Teaming with Opticul Diagnostics will result in a faster development and a superior technology,” Hugues Tariel, president and chief executive officer of Diafir, said in a statement.